Minerva Neurosciences, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Minerva Neurosciences, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $20.00M.
- Minerva Neurosciences, Inc. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $7.37M.
- Minerva Neurosciences, Inc. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $5.18M.
- Minerva Neurosciences, Inc. stock issued during period, value, new issues for the quarter ending 2017-12-31 was -$2.94M.
- Minerva Neurosciences, Inc. stock issued during period, value, new issues for fiscal 2023 was $20.00M.
- Minerva Neurosciences, Inc. stock issued during period, value, new issues for fiscal 2020 was $12.55M.
- Minerva Neurosciences, Inc. stock issued during period, value, new issues for fiscal 2017 was $41.62M.
- Minerva Neurosciences, Inc. stock issued during period, value, new issues for fiscal 2015 was $28.53M, a 44.70% decline from fiscal 2014.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $20.00M 10-K · filed 2025-02-25 | |
| 2023-06-30 | $20.00M 10-Q · filed 2024-11-05 | |
| 2020-12-31 | $12.55M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $7.37M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $5.18M 10-Q · filed 2021-11-08 | |
| 2017-12-31 | -$2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $41.62M 10-K · filed 2019-03-12 |
| 2016-03-31 | $1000.00K 10-Q · filed 2017-05-04 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $28.53M 10-K · filed 2016-03-14 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | |
| 2014-12-31 | -$20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $51.60M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |